JP2017506513A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017506513A5 JP2017506513A5 JP2016551764A JP2016551764A JP2017506513A5 JP 2017506513 A5 JP2017506513 A5 JP 2017506513A5 JP 2016551764 A JP2016551764 A JP 2016551764A JP 2016551764 A JP2016551764 A JP 2016551764A JP 2017506513 A5 JP2017506513 A5 JP 2017506513A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- seq
- item
- vector
- items
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461940339P | 2014-02-14 | 2014-02-14 | |
| US61/940,339 | 2014-02-14 | ||
| PCT/US2015/016057 WO2015123642A1 (en) | 2014-02-14 | 2015-02-16 | Chimeric antigen receptors and methods of making |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019235725A Division JP2020058380A (ja) | 2014-02-14 | 2019-12-26 | キメラ抗原受容体及びその製造方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017506513A JP2017506513A (ja) | 2017-03-09 |
| JP2017506513A5 true JP2017506513A5 (enExample) | 2018-03-08 |
| JP6640726B2 JP6640726B2 (ja) | 2020-02-05 |
Family
ID=53800695
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016551764A Expired - Fee Related JP6640726B2 (ja) | 2014-02-14 | 2015-02-16 | キメラ抗原受容体及びその製造方法 |
| JP2019235725A Withdrawn JP2020058380A (ja) | 2014-02-14 | 2019-12-26 | キメラ抗原受容体及びその製造方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019235725A Withdrawn JP2020058380A (ja) | 2014-02-14 | 2019-12-26 | キメラ抗原受容体及びその製造方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US10125193B2 (enExample) |
| EP (2) | EP3105335B1 (enExample) |
| JP (2) | JP6640726B2 (enExample) |
| KR (1) | KR102375998B1 (enExample) |
| CN (2) | CN113234757B (enExample) |
| AU (2) | AU2015218239B2 (enExample) |
| CA (2) | CA3190002A1 (enExample) |
| DK (1) | DK3105335T3 (enExample) |
| ES (1) | ES2764471T3 (enExample) |
| IL (3) | IL247208B (enExample) |
| MX (2) | MX369513B (enExample) |
| RU (2) | RU2753965C2 (enExample) |
| SG (2) | SG11201606664UA (enExample) |
| WO (1) | WO2015123642A1 (enExample) |
| ZA (2) | ZA201605655B (enExample) |
Families Citing this family (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201505858VA (en) | 2013-01-28 | 2015-09-29 | St Jude Childrens Res Hospital | A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease |
| EP2997134B1 (en) | 2013-05-14 | 2020-06-24 | Board of Regents, The University of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| CA2913052A1 (en) | 2013-05-24 | 2014-11-27 | Board Of Regents, The University Of Texas System | Chimeric antigen receptor-targeting monoclonal antibodies |
| DK3105335T3 (da) | 2014-02-14 | 2020-01-13 | Univ Texas | Kimære antigenreceptorer og fremgangsmåder til fremstilling heraf |
| SG10201808811QA (en) | 2014-04-10 | 2018-11-29 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Method and compositions for cellular immunotherapy |
| EP3805371A1 (en) | 2014-05-15 | 2021-04-14 | National University of Singapore | Modified natural killer cells and uses thereof |
| GB201506423D0 (en) | 2015-04-15 | 2015-05-27 | Tc Biopharm Ltd | Gamma delta T cells and uses thereof |
| CA2964783C (en) | 2014-11-05 | 2024-01-23 | Board Of Regents, The University Of Texas System | Chimeric antigen receptors (car) to selectively target protein complexes |
| CA2964785A1 (en) | 2014-11-05 | 2016-05-12 | Board Of Regents, The University Of Texas System | Gene modified immune effector cells and engineered cells for expansion of immune effector cells |
| US10808230B2 (en) | 2015-02-24 | 2020-10-20 | Board Of Regents, The University Of Texas System | Selection methods for genetically-modified T cells |
| EP3262166A4 (en) | 2015-02-24 | 2018-08-15 | The Regents of The University of California | Binding-triggered transcriptional switches and methods of use thereof |
| JP6775515B2 (ja) | 2015-03-11 | 2020-10-28 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | トランスポザーゼポリペプチド及びその使用 |
| CN107708710A (zh) | 2015-03-17 | 2018-02-16 | 嵌合体生物工程公司 | Smart CAR装置,DE CAR多肽,Side CAR及其使用 |
| WO2016172372A1 (en) * | 2015-04-23 | 2016-10-27 | Baylor College Of Medicine | Nkt-cell subset for in vivo persistence and therapeutic activity and ppropagation of same |
| GB201507368D0 (en) * | 2015-04-30 | 2015-06-17 | Ucl Business Plc | Cell |
| EP3770168A1 (en) | 2015-05-18 | 2021-01-27 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| WO2017011316A1 (en) * | 2015-07-10 | 2017-01-19 | The Trustees Of The University Of Pennsylvania | Treatment of a canine cd20 positive disease or condition using a canine cd20-specific chimeric antigen receptor |
| MX2018001568A (es) | 2015-08-07 | 2019-04-25 | Seattle Children´S Hospital Dba Seattle Children´S Res Institute | Celulas t biespecificas de receptor quimerico de antigeno (car) para focalizacion a tumores solidos. |
| EP3344803B1 (en) * | 2015-09-01 | 2021-08-04 | The Regents of The University of California | Modular polypeptide libraries and methods of making and using same |
| EP3349791A1 (en) | 2015-09-15 | 2018-07-25 | Board of Regents, The University of Texas System | T-cell receptor (tcr)-binding antibodies and uses thereof |
| WO2017075147A1 (en) | 2015-10-27 | 2017-05-04 | Board Of Regents, The University Of Texas System | Chimeric antigen receptor molecules and uses thereof |
| US11052111B2 (en) | 2015-12-08 | 2021-07-06 | Chimera Bioengineering, Inc. | Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses |
| WO2017193059A1 (en) * | 2016-05-06 | 2017-11-09 | The Regents Of The University Of California | Systems and methods for targeting cancer cells |
| US10222369B2 (en) | 2016-05-17 | 2019-03-05 | Chimera Bioengineering, Inc. | Methods for making novel antigen binding domains |
| CN118652336A (zh) | 2016-06-08 | 2024-09-17 | 普瑞赛格恩公司 | Cd33特异性嵌合抗原受体 |
| CN106167527A (zh) * | 2016-06-13 | 2016-11-30 | 长沙郝怡雅医药科技有限公司 | 一种融合蛋白 |
| EP3263595A1 (en) * | 2016-06-30 | 2018-01-03 | Medizinische Hochschule Hannover | Fusion protein for use in the treatment of hvg disease |
| EP3714944A1 (en) | 2019-03-29 | 2020-09-30 | Medizinische Hochschule Hannover | Car for use in the treatment of hvg disease |
| WO2018026953A1 (en) | 2016-08-02 | 2018-02-08 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| CA3034093A1 (en) | 2016-08-23 | 2018-03-01 | The Regents Of The University Of California | Proteolytically cleavable chimeric polypeptides and methods of use thereof |
| CN110121352B (zh) | 2016-09-01 | 2020-12-11 | 嵌合体生物工程公司 | Gold优化的car t-细胞 |
| WO2018064076A1 (en) * | 2016-09-27 | 2018-04-05 | Cero Therapeutics, Inc. | Chimeric engulfment receptor molecules |
| US20190119636A1 (en) | 2017-10-23 | 2019-04-25 | Poseida Therapeutics, Inc. | Modified stem cell memory t cells, methods of making and methods of using same |
| BR112019007100A2 (pt) | 2016-10-07 | 2019-06-25 | Tcr2 Therapeutics Inc | composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão |
| CN110177803A (zh) | 2016-11-22 | 2019-08-27 | T细胞受体治疗公司 | 用于使用融合蛋白进行tcr重新编程的组合物和方法 |
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| MX2019011570A (es) | 2017-03-27 | 2019-11-18 | Nat Univ Singapore | Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales. |
| CN117363636A (zh) | 2017-03-27 | 2024-01-09 | 新加坡国立大学 | 一种编码嵌合受体的多核苷酸 |
| CN107177632B (zh) * | 2017-05-27 | 2020-02-07 | 上海优卡迪生物医药科技有限公司 | 一种基于octs技术的髓系白血病car-t治疗载体及其构建方法和应用 |
| EP3635132A4 (en) | 2017-06-07 | 2021-05-26 | Intrexon Corporation | EXPRESSION OF NOVEL CELL MARKERS |
| CN109337872B (zh) * | 2017-07-27 | 2023-06-23 | 上海细胞治疗研究院 | 高效扩增car-t细胞的人工抗原递呈细胞及其用途 |
| CN107529550A (zh) * | 2017-08-28 | 2018-01-02 | 马晓冬 | 一种基于PiggyBac载体的CD‑19‑CAR‑T系统构建方法 |
| JP2020532987A (ja) * | 2017-09-08 | 2020-11-19 | ポセイダ セラピューティクス，インコーポレイティド | キメラリガンド受容体（ｃｌｒ）介在性の条件遺伝子発現のための組成物および方法 |
| JP7035170B2 (ja) * | 2017-09-15 | 2022-03-14 | レンティジェン・テクノロジー・インコーポレイテッド | 抗ｃｄ１９免疫療法によりがんを処置するための組成物および方法 |
| DK3688032T3 (da) | 2017-09-26 | 2025-12-15 | Cero Therapeutics Holdings Inc | Kimære engulfment-receptormolekyler og anvendelsesfremgangsmåder |
| IL273515B2 (en) | 2017-09-29 | 2026-03-01 | Us Health | T cell receptors that recognize mutated P53 |
| KR102742741B1 (ko) | 2017-10-18 | 2024-12-16 | 프레시전 인코포레이티드 | 스페이서를 포함하는 폴리펩타이드 조성물 |
| US10329543B2 (en) * | 2017-10-23 | 2019-06-25 | Poseida Therapeutics, Inc. | Modified stem cell memory T cells, methods of making and methods of using same |
| CN111886015B (zh) * | 2017-10-31 | 2024-04-26 | 艾洛基治疗公司 | 用于同种异体嵌合抗原受体t细胞的给药的方法和组合物 |
| CN117756946A (zh) * | 2017-11-03 | 2024-03-26 | 莱蒂恩技术公司 | 用于用抗ror1免疫治疗来治疗癌症的组合物和方法 |
| BR112020011017A2 (pt) | 2017-12-22 | 2020-11-17 | Fate Therapeutics, Inc. | células efetoras imunes intensificadas e uso das mesmas |
| CN109970864A (zh) * | 2017-12-28 | 2019-07-05 | 上海细胞治疗研究院 | 一种双向激活共刺激分子受体及其用途 |
| CN111867619A (zh) | 2018-01-03 | 2020-10-30 | 曲生物制品公司 | 过继性细胞治疗的先天寻靶 |
| JP7360174B2 (ja) | 2018-02-09 | 2023-10-12 | ナショナル ユニヴァーシティー オブ シンガポール | ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用 |
| EP3806870A4 (en) | 2018-02-13 | 2021-12-22 | Chimera Bioengineering, Inc. | COORDINATION OF GENE EXPRESSION USING RNA DESSTABILIZATION ELEMENTS |
| US20210017248A1 (en) * | 2018-03-16 | 2021-01-21 | The Regents Of The University Of California | Cellular signaling domain engineering in chimeric antigen receptor-modified regulatory t cells |
| US12291557B2 (en) * | 2018-03-28 | 2025-05-06 | Cero Therapeutics Holdings, Inc. | Chimeric TIM4 receptors and uses thereof |
| RU2020135107A (ru) | 2018-03-28 | 2022-04-29 | Серо Терапьютикс, Инк. | Клеточные иммунотерапевтические композиции и их применения |
| AU2019243315A1 (en) | 2018-03-29 | 2020-09-24 | Fate Therapeutics, Inc. | Engineered immune effector cells and use thereof |
| US12441787B2 (en) | 2018-04-02 | 2025-10-14 | National University Of Singapore | Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells |
| CN110577605A (zh) * | 2018-06-11 | 2019-12-17 | 浙江启新生物技术有限公司 | 一种靶向多发性骨髓瘤多种抗原的嵌合抗原受体t（car-t）细胞的构建方法及其应用 |
| CN110850068B (zh) * | 2018-08-21 | 2023-08-15 | 上海恒润达生生物科技股份有限公司 | 一种嵌合抗原受体亲和力检测方法 |
| WO2020044239A1 (en) | 2018-08-29 | 2020-03-05 | National University Of Singapore | A method to specifically stimulate survival and expansion of genetically-modified immune cells |
| CN113226340A (zh) | 2018-11-26 | 2021-08-06 | 恩卡尔塔公司 | 同时扩增多种免疫细胞类型的方法、相关组合物及其在癌症免疫疗法中的用途 |
| JP2022510207A (ja) | 2018-12-02 | 2022-01-26 | フェイト セラピューティクス，インコーポレイテッド | 増強されたｉＰＳＣ派生エフェクター細胞を使用した免疫療法 |
| CN111253487B (zh) * | 2018-12-03 | 2024-02-02 | 广东东阳光药业股份有限公司 | Cd19抗体及其应用 |
| KR20250116790A (ko) | 2018-12-12 | 2025-08-01 | 카이트 파마 인코포레이티드 | 키메라 항원 수용체 및 car-t 세포 및 사용 방법 |
| CN109777784B (zh) * | 2019-02-22 | 2021-12-31 | 上海尚泰生物技术有限公司 | 一种增强向肿瘤部位迁移的嵌合抗原受体载体构建方法与应用 |
| KR20210137085A (ko) | 2019-03-05 | 2021-11-17 | 엔카르타, 인크. | Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도 |
| WO2020209934A1 (en) * | 2019-04-11 | 2020-10-15 | Massachusetts Institute Of Technology | Novel chimeric antigen receptors and libraries |
| US20210046117A1 (en) | 2019-08-18 | 2021-02-18 | Chimera Bioengineering, Inc. | Combination Therapy with Gold Controlled Transgenes |
| WO2021046243A2 (en) | 2019-09-03 | 2021-03-11 | Myeloid Therapeutics, Inc. | Methods and compositions for genomic integration |
| CN114651003A (zh) | 2019-09-10 | 2022-06-21 | 黑曜石疗法公司 | 用于可调调节的ca2-il15融合蛋白 |
| GB201915384D0 (en) * | 2019-10-23 | 2019-12-04 | Ucl Business Ltd | Vector |
| CN110964750A (zh) * | 2019-11-13 | 2020-04-07 | 沣潮医药科技（上海）有限公司 | 携带基因元件组合的嵌合抗原受体细胞文库、制备和筛选方法及用途 |
| CN111304244A (zh) * | 2019-11-13 | 2020-06-19 | 沣潮医药科技（上海）有限公司 | 携带基因元件组合的载体组件、受体细胞文库、制备和筛选方法及用途 |
| KR20220130158A (ko) | 2020-01-23 | 2022-09-26 | 더 칠드런스 메디칼 센터 코포레이션 | 인간 만능 줄기 세포로부터의 무-간질 t 세포 분화 |
| KR102937659B1 (ko) | 2020-02-19 | 2026-03-10 | 우시 바이올로직스 아일랜드 리미티드 | 강화된 발현 시스템 및 그 사용방법 |
| CA3173673A1 (en) | 2020-04-23 | 2021-10-28 | The Regents Of The University Of California | Genetically engineered phagocytes, and related compositions, vectors, methods and systems |
| AU2021278356A1 (en) | 2020-05-27 | 2022-11-03 | Antion Biosciences Sa | Adapter molecules to re-direct CAR T cells to an antigen of interest |
| GB202008688D0 (en) * | 2020-06-09 | 2020-07-22 | Cancer Research Tech Ltd | Chimeric antigen receptor cell |
| KR20230040337A (ko) | 2020-06-19 | 2023-03-22 | 페이트 세러퓨틱스, 인코포레이티드 | 면역요법 사용을 위한 iPSC-유래 이펙터 세포 유형들의 조합 |
| CN113913458A (zh) * | 2020-07-09 | 2022-01-11 | 杭州优凯瑞医药科技有限公司 | 非病毒方法制备稳定高表达嵌合受体的nk细胞 |
| CN112062859B (zh) * | 2020-07-24 | 2022-08-09 | 沣潮医药科技（上海）有限公司 | 用于病原体清除的嵌合抗原受体及其应用 |
| JP7868033B2 (ja) | 2020-08-14 | 2026-06-01 | セロ・セラピューティクス・ホールディングス・インコーポレイテッド | キメラｔｉｍ受容体およびその使用 |
| CA3208273A1 (en) | 2021-01-20 | 2022-07-28 | Coding Bio Limited | Methods for high throughput screening of chimeric antigen receptors |
| US20240197881A1 (en) * | 2021-04-23 | 2024-06-20 | Sorrento Therapeutics, Inc. | Dimeric Antigen Receptors (DARs) that Bind GD2 |
| WO2022241029A1 (en) | 2021-05-11 | 2022-11-17 | Myeloid Therapeutics, Inc. | Methods and compositions for genomic integration |
| EP4408894A4 (en) | 2021-09-29 | 2025-08-20 | Chimera Bioengineering Inc | Compositions and methods for anti-tnmuc1 gold car t-cells |
| US20250135002A1 (en) * | 2022-02-04 | 2025-05-01 | Duke University | Compositions for and method of effecting tumor cell death |
| US20250136689A1 (en) * | 2022-02-04 | 2025-05-01 | Duke University | Compositions for and methods of treating hematological cancers |
| KR20250004622A (ko) | 2022-04-08 | 2025-01-08 | 페이트 세러퓨틱스, 인코포레이티드 | 종양 표적화를 위한 키메라 항원 수용체 |
| KR20250005097A (ko) | 2022-04-08 | 2025-01-09 | 페이트 세러퓨틱스, 인코포레이티드 | 고형 종양 표적화 골격을 갖는 세포 및 이의 용도 |
| WO2024150828A1 (ja) * | 2023-01-12 | 2024-07-18 | 積水化学工業株式会社 | 遺伝子導入方法 |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8211422B2 (en) | 1992-03-18 | 2012-07-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric receptor genes and cells transformed therewith |
| IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| WO1996027392A1 (en) | 1995-03-08 | 1996-09-12 | The Scripps Research Institute | Antigen presenting system and methods for activation of t-cells |
| IL126843A (en) | 1996-05-23 | 2007-06-17 | Scripps Research Inst | Mhc class ii antigen-presenting systems and methods for activating cd4+t cells in vitro |
| DK0973928T3 (da) | 1997-03-11 | 2010-08-09 | Univ Minnesota | DNA-baseret transposonsystem til indføring af nukleinsyre i DNA i en celle |
| EP0972039A1 (en) | 1997-03-25 | 2000-01-19 | Morphogenesis, Inc. | Universal stem cells |
| AU2472400A (en) | 1998-10-20 | 2000-05-08 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
| US6790662B1 (en) | 1999-03-12 | 2004-09-14 | Ortho-Mcneil Pharmaceutical, Inc. | Method of isolating CD8+ cells, and related hybridoma cells antibodies and polypeptides |
| US7446179B2 (en) | 2000-11-07 | 2008-11-04 | City Of Hope | CD19-specific chimeric T cell receptor |
| US20040071671A1 (en) | 2001-02-20 | 2004-04-15 | Leturcq Didier J. | Cell therapy method for the treatment of tumors |
| US20030157561A1 (en) * | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
| US20030171546A1 (en) | 2001-04-30 | 2003-09-11 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| US7514240B2 (en) | 2002-02-05 | 2009-04-07 | Japan Science And Technology Agency | EGR-EGFR complex |
| US20030194704A1 (en) | 2002-04-03 | 2003-10-16 | Penn Sharron Gaynor | Human genome-derived single exon nucleic acid probes useful for gene expression analysis two |
| WO2003089618A2 (en) | 2002-04-22 | 2003-10-30 | Regents Of The University Of Minnesota | Transposon system and methods of use |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| EP1590485A2 (en) | 2003-01-30 | 2005-11-02 | Applera Corporation | Genetic polymorphisms associated with rheumatoid arthritis, methods of detection and uses thereof |
| US8802643B1 (en) | 2003-05-30 | 2014-08-12 | University Of South Florida | Method for the treatment of malignancies |
| NZ570709A (en) | 2003-06-13 | 2010-04-30 | Univ Pennsylvania | Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same |
| JP4733635B2 (ja) | 2003-07-31 | 2011-07-27 | イミューノメディクス、インコーポレイテッド | 抗ｃｄ１９抗体 |
| US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| US20070066802A1 (en) * | 2003-08-20 | 2007-03-22 | Geiger Terrance L | Chimeric receptors with disrupted dileucine motifs |
| US20130266551A1 (en) * | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
| US20050113564A1 (en) | 2003-11-05 | 2005-05-26 | St. Jude Children's Research Hospital | Chimeric receptors with 4-1BB stimulatory signaling domain |
| US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| PT1809321E (pt) | 2004-10-08 | 2012-05-17 | Us Gov Health & Human Serv | Imunoterapia adotiva com sobrevivência aumentada de linfócitos |
| WO2007001677A2 (en) | 2005-05-17 | 2007-01-04 | University Of Connecticut | Compositions and methods for immunomodulation in an organism |
| EP1913149A4 (en) | 2005-07-26 | 2009-08-05 | Sangamo Biosciences Inc | TARGETED INTEGRATION AND EXPRESSION OF EXOGENOUS NUCLEIC ACID SEQUENCES |
| US20070036773A1 (en) | 2005-08-09 | 2007-02-15 | City Of Hope | Generation and application of universal T cells for B-ALL |
| EP1777294A1 (en) | 2005-10-20 | 2007-04-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins |
| CA2643337C (en) | 2006-03-01 | 2016-01-12 | Janssen Pharmaceutica N.V. | Cancer treatment combining lymphodepleting agent with ctls and cytokines |
| US20070283453A1 (en) | 2006-05-31 | 2007-12-06 | Juan Carlos Rodriguez Cimadevilla | Animal models of tumor metastasis and toxicity |
| RU2355763C2 (ru) | 2006-09-13 | 2009-05-20 | Закрытое акционерное общество "Научно-исследовательский институт Аджиномото-Генетика" (ЗАО АГРИ) | Мутантная ацетолактатсинтаза и способ продукции разветвленных l-аминокислот |
| CN101548008B (zh) | 2006-10-04 | 2013-04-17 | 詹森药业有限公司 | 失活的人工抗原提呈细胞的制备及其在细胞疗法中的用途 |
| CN101573380A (zh) * | 2006-10-12 | 2009-11-04 | 健泰科生物技术公司 | 针对淋巴毒素-α的抗体 |
| US8389282B2 (en) | 2007-03-30 | 2013-03-05 | Memorial Sloan-Kettering Cancer Center | Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes |
| EP2173378B1 (en) | 2007-06-27 | 2014-03-19 | Admune Therapeutics LLC | Complexes of il-15 and il-15ralpha and uses thereof |
| WO2009091826A2 (en) * | 2008-01-14 | 2009-07-23 | The Board Of Regents Of The University Of Texas System | Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car) |
| WO2010008564A2 (en) | 2008-07-16 | 2010-01-21 | Recombinetics | Plaice dna transposon system |
| EP2321407A4 (en) | 2008-09-11 | 2012-07-18 | Univ Florida | SYSTEM AND METHOD FOR THE PRODUCTION OF T-CELLS |
| KR20150036824A (ko) | 2009-03-20 | 2015-04-07 | 제넨테크, 인크. | 이중특이적 항-ｈｅｒ 항체 |
| JP5934099B2 (ja) | 2009-10-01 | 2016-06-15 | アメリカ合衆国 | 抗血管内皮増殖因子受容体−２キメラ抗原受容体及び癌の治療のためのその使用 |
| WO2011059836A2 (en) | 2009-10-29 | 2011-05-19 | Trustees Of Dartmouth College | T cell receptor-deficient t cell compositions |
| US8956828B2 (en) | 2009-11-10 | 2015-02-17 | Sangamo Biosciences, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
| US9242014B2 (en) | 2010-06-15 | 2016-01-26 | The Regents Of The University Of California | Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof |
| CA2805442C (en) | 2010-07-21 | 2020-05-12 | Sangamo Biosciences, Inc. | Methods and compositions for modification of an hla locus |
| JP6251570B2 (ja) | 2010-09-21 | 2017-12-20 | アルター・バイオサイエンス・コーポレーション | 多量体ｉｌ−１５可溶性融合分子並びにその製造及び使用方法 |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| JP2014509841A (ja) * | 2011-01-18 | 2014-04-24 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 癌を治療するための組成物および方法 |
| KR20140060541A (ko) | 2011-09-16 | 2014-05-20 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 암을 치료하기 위한 rna 조작된 t 세포 |
| US9708384B2 (en) * | 2011-09-22 | 2017-07-18 | The Trustees Of The University Of Pennsylvania | Universal immune receptor expressed by T cells for the targeting of diverse and multiple antigens |
| JP6267644B2 (ja) | 2011-10-20 | 2018-01-24 | アメリカ合衆国 | 抗ｃｄ２２キメラ抗原受容体 |
| US9272002B2 (en) * | 2011-10-28 | 2016-03-01 | The Trustees Of The University Of Pennsylvania | Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting |
| JP6117515B2 (ja) * | 2011-11-01 | 2017-04-19 | 国立大学法人名古屋大学 | 髄膜腫治療用医薬組成物 |
| WO2013074916A1 (en) * | 2011-11-18 | 2013-05-23 | Board Of Regents, The University Of Texas System | Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla |
| CN108341873B (zh) | 2011-12-05 | 2022-03-25 | 诺华股份有限公司 | 表皮生长因子受体3(her3)的抗体 |
| CA3285826A1 (en) * | 2012-02-22 | 2026-03-02 | The Trustees Of The University Of Pennsylvania | Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer |
| EP2817330B1 (en) * | 2012-02-22 | 2020-07-08 | The Trustees of the University of Pennsylvania | Use of icos-based cars to enhance antitumor activity and car persistence |
| AU2013246443B2 (en) | 2012-04-11 | 2017-04-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors targeting B-cell maturation antigen |
| US20130280220A1 (en) * | 2012-04-20 | 2013-10-24 | Nabil Ahmed | Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes |
| SG10201806573TA (en) | 2012-05-25 | 2018-09-27 | Cellectis | Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy |
| WO2014037807A2 (en) | 2012-09-07 | 2014-03-13 | Biolamina Ab | Stem cell bank |
| AU2013204922B2 (en) | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
| HK1220614A1 (zh) | 2013-03-10 | 2017-05-12 | Baylor College Of Medicine | 耐化疗免疫细胞 |
| US9657105B2 (en) * | 2013-03-15 | 2017-05-23 | City Of Hope | CD123-specific chimeric antigen receptor redirected T cells and methods of their use |
| EP2997134B1 (en) * | 2013-05-14 | 2020-06-24 | Board of Regents, The University of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| CA2913052A1 (en) | 2013-05-24 | 2014-11-27 | Board Of Regents, The University Of Texas System | Chimeric antigen receptor-targeting monoclonal antibodies |
| US9907820B2 (en) | 2013-10-25 | 2018-03-06 | Board Of Regents, The University Of Texas System | Polyclonal gamma delta T cells for immunotherapy |
| DK3105335T3 (da) * | 2014-02-14 | 2020-01-13 | Univ Texas | Kimære antigenreceptorer og fremgangsmåder til fremstilling heraf |
| CN122399016A (zh) | 2014-03-15 | 2026-07-17 | 诺华股份有限公司 | 使用嵌合抗原受体治疗癌症 |
| US20170158749A1 (en) | 2014-04-23 | 2017-06-08 | Board Of Regents, The University Of Texas System | Chimeric antigen receptors (car) and methods for making and using the same |
| KR20160145186A (ko) | 2014-04-24 | 2016-12-19 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 입양 세포 요법 생성물을 생성하기 위한 유도 만능 줄기 세포의 응용 |
| EP3805371A1 (en) | 2014-05-15 | 2021-04-14 | National University of Singapore | Modified natural killer cells and uses thereof |
| US10335460B2 (en) | 2014-07-29 | 2019-07-02 | Novartis Ag | IL-15 and IL-15Rα heterodimer dose escalation regimens for treating conditions |
| CA2964785A1 (en) | 2014-11-05 | 2016-05-12 | Board Of Regents, The University Of Texas System | Gene modified immune effector cells and engineered cells for expansion of immune effector cells |
| CA2964783C (en) | 2014-11-05 | 2024-01-23 | Board Of Regents, The University Of Texas System | Chimeric antigen receptors (car) to selectively target protein complexes |
| US10808230B2 (en) | 2015-02-24 | 2020-10-20 | Board Of Regents, The University Of Texas System | Selection methods for genetically-modified T cells |
| JP6775515B2 (ja) | 2015-03-11 | 2020-10-28 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | トランスポザーゼポリペプチド及びその使用 |
| EP3349791A1 (en) | 2015-09-15 | 2018-07-25 | Board of Regents, The University of Texas System | T-cell receptor (tcr)-binding antibodies and uses thereof |
| AU2016326575A1 (en) | 2015-09-25 | 2018-04-12 | Altor Bioscience Corporation | Interleukin-15 superagonist significantly enhances graft-versus-tumor activity |
| WO2017075147A1 (en) | 2015-10-27 | 2017-05-04 | Board Of Regents, The University Of Texas System | Chimeric antigen receptor molecules and uses thereof |
| US20190117690A1 (en) | 2016-04-06 | 2019-04-25 | The University State Of America As Represented By The Secretary Of The Department Of Health And Hum | Use of heterodimeric il-15 in adoptive cell transfer |
| CA3049652A1 (en) * | 2017-01-10 | 2018-07-19 | Intrexon Corporation | Modulating expression of polypeptides via new gene switch expression systems |
-
2015
- 2015-02-16 DK DK15749056.6T patent/DK3105335T3/da active
- 2015-02-16 ES ES15749056T patent/ES2764471T3/es active Active
- 2015-02-16 CA CA3190002A patent/CA3190002A1/en active Pending
- 2015-02-16 CN CN202110505479.4A patent/CN113234757B/zh active Active
- 2015-02-16 EP EP15749056.6A patent/EP3105335B1/en active Active
- 2015-02-16 AU AU2015218239A patent/AU2015218239B2/en not_active Ceased
- 2015-02-16 US US15/118,245 patent/US10125193B2/en active Active
- 2015-02-16 WO PCT/US2015/016057 patent/WO2015123642A1/en not_active Ceased
- 2015-02-16 KR KR1020167024697A patent/KR102375998B1/ko not_active Expired - Fee Related
- 2015-02-16 CN CN201580017207.2A patent/CN106414748B/zh not_active Expired - Fee Related
- 2015-02-16 SG SG11201606664UA patent/SG11201606664UA/en unknown
- 2015-02-16 JP JP2016551764A patent/JP6640726B2/ja not_active Expired - Fee Related
- 2015-02-16 RU RU2016136370A patent/RU2753965C2/ru active
- 2015-02-16 RU RU2021123419A patent/RU2021123419A/ru unknown
- 2015-02-16 EP EP19200716.9A patent/EP3656864A1/en not_active Withdrawn
- 2015-02-16 CA CA2938887A patent/CA2938887C/en active Active
- 2015-02-16 MX MX2016010566A patent/MX369513B/es active IP Right Grant
- 2015-02-16 SG SG10201811816RA patent/SG10201811816RA/en unknown
-
2016
- 2016-08-10 IL IL247208A patent/IL247208B/en active IP Right Grant
- 2016-08-12 MX MX2019009295A patent/MX2019009295A/es unknown
- 2016-08-16 ZA ZA2016/05655A patent/ZA201605655B/en unknown
-
2018
- 2018-09-28 US US16/145,790 patent/US20190085079A1/en not_active Abandoned
- 2018-11-16 ZA ZA2018/07750A patent/ZA201807750B/en unknown
-
2019
- 2019-04-10 AU AU2019202514A patent/AU2019202514B2/en not_active Ceased
- 2019-12-26 JP JP2019235725A patent/JP2020058380A/ja not_active Withdrawn
-
2020
- 2020-01-26 IL IL272264A patent/IL272264B/en active IP Right Grant
-
2021
- 2021-02-26 US US17/187,074 patent/US12065490B2/en active Active
- 2021-03-25 IL IL281819A patent/IL281819B2/en unknown
-
2024
- 2024-07-05 US US18/764,962 patent/US20250002579A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016136370A (ru) | Химерные антигенные рецепторы и способы их получения | |
| Nigro et al. | NK-mediated antibody-dependent cell-mediated cytotoxicity in solid tumors: biological evidence and clinical perspectives | |
| AU2014228962B2 (en) | Multimerization technologies | |
| JP2019513347A5 (enExample) | ||
| CA3113409A1 (en) | Dual acting cd1d immunoglobulin | |
| JP2015527070A5 (enExample) | ||
| CN107880128B (zh) | 一种抗cd19的全人源抗体或抗体片段及其方法和应用 | |
| JP2018529327A5 (enExample) | ||
| CN112028996A (zh) | 靶向bcma的单域抗体及其用途 | |
| US20210284729A1 (en) | Genetic modified pluri- or multipotent stem cells and uses thereof | |
| RU2017121115A (ru) | Генетически модифицированные гамма дельта т-клетки | |
| JP2016537966A (ja) | 分子 | |
| JP2017514471A5 (enExample) | ||
| JP2025508050A (ja) | Ｃｄ７０指向性がん免疫療法のための多重遺伝子編集細胞 | |
| WO2020068702A1 (en) | Chimeric receptor proteins and uses thereof | |
| CN114025774A (zh) | 可切换嵌合抗原受体工程化的人自然杀伤细胞 | |
| WO2025213573A1 (zh) | 细胞免疫疗法的组合物和方法 | |
| CN117004604A (zh) | 一种ciita基因被敲除的工程化免疫细胞及其用途 | |
| JP2024531910A5 (enExample) | ||
| CN115873801A (zh) | 工程化免疫细胞及其用途 | |
| AU2024276506A1 (en) | Immune effector cell and use thereof | |
| EP4188952A1 (en) | Anti-cd22 single domain antibodies and therapeutic constructs | |
| WO2023016284A1 (zh) | 工程化免疫细胞及其用途 | |
| CN121194791A (zh) | 免疫细胞联合疗法 | |
| JP2022109936A (ja) | キラー免疫グロブリン様受容体（ｋｉｒ）ファミリーのシグナル伝達を標的とするモノクローナル抗体 |